Evercore ISI maintains Veeva Systems' In-Line rating, raises PT to $295.
ByAinvest
Thursday, Aug 28, 2025 9:04 am ET1min read
VEEV--
Veeva Systems reported total revenue of $789.1 million, representing a 17% year-over-year growth and exceeding expectations of approximately $768 million. Earnings per share came in at $1.99, ahead of the consensus estimate of $1.90. However, billings of $666 million fell slightly short of the $666.5 million consensus. The company maintains impressive profitability with a 75.5% gross margin and strong return metrics, earning it a "GREAT" financial health score from InvestingPro [1].
The company raised its full-year fiscal 2026 guidance across all metrics. Total revenue guidance was increased by $40 million to a range of $3.134-$3.140 billion. Operating income guidance was raised by $28 million to $1.388 billion, while normalized billings guidance increased by $35 million to $3.355 billion. This outlook builds on the company’s strong track record, with revenue growing at 14.78% over the last twelve months [1].
Crossix was identified as the key driver of commercial solutions growth, with revenue up 13% year-over-year to $307.5 million. The company’s partnership with IQVIA was highlighted as bringing multiple benefits that should unfold over time, particularly enhancing Veeva Nitro’s value in commercial analytics [1].
Veeva has secured verbal commitments from two additional top-20 biopharma companies, bringing the total to 9 of the top 20, while its CRM product secured another verbal commitment, bringing that total to 3. Vault migrations are reportedly progressing well, with two top-20 biopharmas now live [1].
In other recent news, Veeva Systems reported impressive financial results for the fiscal second quarter, exceeding market expectations. The company achieved revenue of $789.1 million, marking a 17% increase year-over-year and surpassing consensus estimates of $768 million. Adjusted operating income reached $352.6 million, a 26% rise from the previous year, also beating expectations. Analysts responded positively to these results, with BTIG, Raymond James, and Baird adjusting their price targets upwards [1].
References:
[1] https://www.investing.com/news/analyst-ratings/veeva-systems-stock-price-target-raised-to-295-by-evercore-isi-93CH-4214407
Evercore ISI maintains Veeva Systems' In-Line rating, raises PT to $295.
Evercore ISI has raised its price target on Veeva Systems (NYSE:VEEV) to $295.00 from $285.00, while maintaining an "In Line" rating following the company’s quarterly earnings report. The stock is currently trading near its 52-week high of $296.72, with InvestingPro data indicating the stock is slightly overvalued at current levels [1].Veeva Systems reported total revenue of $789.1 million, representing a 17% year-over-year growth and exceeding expectations of approximately $768 million. Earnings per share came in at $1.99, ahead of the consensus estimate of $1.90. However, billings of $666 million fell slightly short of the $666.5 million consensus. The company maintains impressive profitability with a 75.5% gross margin and strong return metrics, earning it a "GREAT" financial health score from InvestingPro [1].
The company raised its full-year fiscal 2026 guidance across all metrics. Total revenue guidance was increased by $40 million to a range of $3.134-$3.140 billion. Operating income guidance was raised by $28 million to $1.388 billion, while normalized billings guidance increased by $35 million to $3.355 billion. This outlook builds on the company’s strong track record, with revenue growing at 14.78% over the last twelve months [1].
Crossix was identified as the key driver of commercial solutions growth, with revenue up 13% year-over-year to $307.5 million. The company’s partnership with IQVIA was highlighted as bringing multiple benefits that should unfold over time, particularly enhancing Veeva Nitro’s value in commercial analytics [1].
Veeva has secured verbal commitments from two additional top-20 biopharma companies, bringing the total to 9 of the top 20, while its CRM product secured another verbal commitment, bringing that total to 3. Vault migrations are reportedly progressing well, with two top-20 biopharmas now live [1].
In other recent news, Veeva Systems reported impressive financial results for the fiscal second quarter, exceeding market expectations. The company achieved revenue of $789.1 million, marking a 17% increase year-over-year and surpassing consensus estimates of $768 million. Adjusted operating income reached $352.6 million, a 26% rise from the previous year, also beating expectations. Analysts responded positively to these results, with BTIG, Raymond James, and Baird adjusting their price targets upwards [1].
References:
[1] https://www.investing.com/news/analyst-ratings/veeva-systems-stock-price-target-raised-to-295-by-evercore-isi-93CH-4214407

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet